Norovirus Infection in Young Nicaraguan Children Induces Durable and Genotype-Specific Antibody Immunity
Authors:
- Paul D. Brewer-JensenPBPaul D. Brewer-Jensen
- Yaoska ReyesYRYaoska Reyes
- Sylvia Becker-DrepsSBSylvia Becker-Dreps
- Fredman GonzálezFGFredman González
- Michael L. MalloryMMMichael L. Mallory
- Lester GutiérrezLGLester Gutiérrez
- Omar ZepedaOZOmar Zepeda
- Edwing CentenoECEdwing Centeno
- Nadja VielotNVNadja Vielot
- Marta Diez-ValcarceMDMarta Diez-Valcarce
- Jan VinjéJVJan Vinjé
- Ralph BaricRBRalph Baric
Open Access
Abstract
There are significant challenges to the development of a pediatric norovirus vaccine, mainly due to the antigenic diversity among strains infecting young children. Characterizing human norovirus serotypes and understanding norovirus immunity in naïve children would provide key information for designing rational vaccine platforms. In this study, 26 Nicaraguan children experiencing their first norovirus acute gastroenteritis (AGE) episode during the first 18 months of life were investigated. We used a surrogate neutralization assay that measured antibodies blocking the binding of 13 different norovirus virus-like particles (VLPs) to histo-blood group antigens (HBGAs) in pre- and post-infection sera. To assess for asymptomatic norovirus infections, stools from asymptomatic children were collected monthly, screened for norovirus by RT-qPCR and genotyped by sequencing. Seroconversion of an HBGA-blocking antibody matched the infecting genotype in 25 (96%) of the 26 children. A subset of 13 (50%) and 4 (15%) of the 26 children experienced monotypic GII and GI seroconversion, respectively, strongly suggesting a type-specific response in naïve children, and 9 (35%) showed multitypic seroconversion. The most frequent pairing in multitypic seroconversion (8/12) were GII.4 Sydney and GII.12 noroviruses, both co-circulating at the time. Blocking antibody titers to these two genotypes did not correlate with each other, suggesting multiple exposure rather than cross-reactivity between genotypes. In addition, GII titers remained consistent for at least 19 months post-infection, demonstrating durable immunity. In conclusion, the first natural norovirus gastroenteritis episodes in these young children were dominated by a limited number of genotypes and induced responses of antibodies blocking binding of norovirus VLPs in a genotype-specific manner, suggesting that an effective pediatric norovirus vaccine likely needs to be multivalent and include globally dominant genotypes. The duration of protection from natural infections provides optimism for pediatric norovirus vaccines administered early in life.Keywords
Funding Information
- National Institute of Allergy and Infectious Diseases (K24AI141744, R01AI127845, R01AI148260)
- Wellcome Trust (203268/Z/16/Z)
- Fogarty International Center (D43TW010923)
This publication has 61 references indexed in Scilit:
- Duration of Immunity to Norovirus GastroenteritisEmerging Infectious Diseases, 2013
- Immunogenetic Mechanisms Driving Norovirus GII.4 Antigenic VariationPLOS Pathogens, 2012
- Immunogenicity and specificity of norovirus Consensus GII.4 virus-like particles in monovalent and bivalent vaccine formulationsVaccine, 2012
- Norovirus Vaccine against Experimental Human Norwalk Virus IllnessNew England Journal of Medicine, 2011
- Serological Correlate of Protection against Norovirus‐Induced GastroenteritisThe Journal of Infectious Diseases, 2010
- Rapid Evolution of Pandemic Noroviruses of the GII.4 LineagePLOS Pathogens, 2010
- Elucidation of strain-specific interaction of a GII-4 norovirus with HBGA receptors by site-directed mutagenesis studyVirology, 2008
- Mechanisms of GII.4 Norovirus Persistence in Human PopulationsPLOS Medicine, 2008
- Use of TaqMan Real-Time Reverse Transcription-PCR for Rapid Detection, Quantification, and Typing of NorovirusJournal of Clinical Microbiology, 2006
- Clinical Immunity in Acute Gastroenteritis Caused by Norwalk AgentNew England Journal of Medicine, 1977